2.3 The cost per item from the company's submission is £11,060 per 140‑mg vial (excluding VAT; British national formulary online accessed July 2020). The company estimates that the average cost of a course of treatment is £50,416.
2.4 The company has a commercial arrangement. This makes polatuzumab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.